List view / Grid view
Biomarkers are a naturally occurring molecule, gene, or characteristic by which a particular disease can be identified.
29 October 2014 | By Probiodrug AG
Probiodrug AG, a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, has announced it is the Silver sponsor of the 5th Biannual NUBIN Symposium on Biomarkers in Neurodegenerative Disease taking place on October 29th and 30th in Amsterdam.
Macrocyclic compounds (see Figure 1) have fascinated medicinal chemists for generations. The first ones which have been characterised are the naturally occurring cyclodextrins (CDs), cyclic oligomers of glucose, which can be obtained by bacterial synthesis from starch. Calixarenes (CXs) were among the first man-made macrocycles, followed by crown ethers (Pedersen,…
3 October 2014 | By GTCbio
From 7-10 October 2014, GTCbio will proudly present its Drug Discovery Week Europe event in the beautiful city of Dublin, Ireland...
29 September 2014 | By Caris Life Sciences
Caris Life Sciences announced important new data presented at the European Society for Medical Oncology Annual Conference, highlighting how tumour profiling with Caris Molecular Intelligence can help transform cancer care...
14 August 2014 | By AstraZeneca
AstraZeneca announced the start of the Phase III programme for tralokinumab, a potential treatment for patients with severe, inadequately controlled asthma, developed by MedImmune, the company’s global biologics research and development arm...
9 July 2014 | By Fraunhofer IME
The operative business of European ScreeningPort GmbH has been integrated into the Fraunhofer Institute for Molecular Biology and Applied Ecology IME located in Aachen...
7 July 2014 | By Myriad RBM
Collaboration will focus on development of novel diagnostic tests for dialysis patients...
7 July 2014 | By Oxford Global
Oxford Global Q&A Session with Brian Pollok, Entrepreneur-In-Residence, University of Virginia...
29 May 2014 | By GTCBio
John Herrmann, Chief Science Officer of Global External Research & Development, Oncology at Eli Lilly To Give a Keynote Presentation on “Partnering with Lilly Oncology: Current Priorities, NYC Innovation Hub Model & Possible Future States” at the Novel Cancer Therapeutics Summit 2014...
16 May 2014 | By Oxford Global Conferences
Registration is now closing for Oxford Global’s Pharma R&D Europe Series, the leading pharmaceutical discussion forum in Europe...
9 May 2014 | By Guido Rasi, Professor Sir Mark Pepys, Kenji Schorpp et al.
We are delighted to welcome you to the inaugural issue of European Drug Target Review, a magazine focused on the changing landscape of the drug discovery industry...
Clearly what is needed is a synergistic collaboration bringing together the respective competence and expertise of academia and industry. All the major pharmaceutical companies have recognised this need and have introduced a range of different models for association with academia and small biotech or biopharma companies. Attempted solutions range from…
The ability to individualise a patient’s care has become a particularly pressing issue in the field of cancer therapeutics as there is a growing recognition that both the global incidence of cancer is steadily rising and the associated costs in terms of treatment and lost productivity are ever increasing. Advances…
